Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056693 · ClinicalTrials.gov registry record · Phase 2
Treatment With SU11248 in Patients With Neuroendocrine Tumors
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT00056693: Completed Phase 2 study, sponsored by Pfizer.
NCT00056693 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 107 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00056693, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.
Interventions
- DRUG Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2003-04 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
What the finished NCT00056693 record still lists
NCT00056693 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 1 intervention - of which Sunitinib is the first listed.
NCT00056693 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00056693 about?
NCT00056693 is a clinical study titled "Treatment With SU11248 in Patients With Neuroendocrine Tumors". To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.
What is the current status of trial NCT00056693?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2003-04. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00056693?
The interventions under investigation include: Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00056693?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00056693's enrollment target sits among peer trials
107 646th of 2000 higher than 1,353 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia